ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis
USA - NASDAQ:ORGO - US68621F1021 - Common Stock
5.63 USD
+1.74 (+44.73%)
5.75 USD
+0.12 (+2.13%)
ORGO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ORGO had positive earnings in the past year.
In the past year ORGO has reported a negative cash flow from operations.
ORGO had positive earnings in 4 of the past 5 years.
In the past 5 years ORGO always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of -3.38%, ORGO belongs to the best of the industry, outperforming 87.83% of the companies in the same industry.
ORGO has a better Return On Equity (-4.32%) than 89.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.38% | ||
| ROE | -4.32% | ||
| ROIC | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ORGO has declined.
The Gross Margin of ORGO (74.58%) is better than 83.15% of its industry peers.
ORGO's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ORGO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.58% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
ORGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ORGO has been reduced compared to 1 year ago.
ORGO has more shares outstanding than it did 5 years ago.
ORGO has a better debt/assets ratio than last year.
2.2 Solvency
ORGO has an Altman-Z score of 4.09. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
ORGO has a Altman-Z score of 4.09. This is in the better half of the industry: ORGO outperforms 73.41% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ORGO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, ORGO is in line with its industry, outperforming 50.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.09 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
A Current Ratio of 3.95 indicates that ORGO has no problem at all paying its short term obligations.
With a Current ratio value of 3.95, ORGO perfoms like the industry average, outperforming 45.69% of the companies in the same industry.
A Quick Ratio of 3.45 indicates that ORGO has no problem at all paying its short term obligations.
The Quick ratio of ORGO (3.45) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.95 | ||
| Quick Ratio | 3.45 |
3. Growth
3.1 Past
ORGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -63.64%.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
Looking at the last year, ORGO shows a quite strong growth in Revenue. The Revenue has grown by 11.29% in the last year.
ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.05% yearly.
EPS 1Y (TTM)-63.64%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)11.29%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
3.2 Future
Based on estimates for the next years, ORGO will show a very strong growth in Earnings Per Share. The EPS will grow by 46.59% on average per year.
Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 12.92% on average per year.
EPS Next Y-136%
EPS Next 2Y36.38%
EPS Next 3Y46.59%
EPS Next 5YN/A
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 140.75, which means the current valuation is very expensive for ORGO.
Compared to the rest of the industry, the Price/Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 90.45% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.83, ORGO is valued quite expensively.
The Price/Forward Earnings ratio is 17.81, which indicates a rather expensive current valuation of ORGO.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaply inside the industry as 96.44% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ORGO to the average of the S&P500 Index (32.68), we can say ORGO is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 140.75 | ||
| Fwd PE | 17.81 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaply inside the industry as 89.70% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 133.2 |
4.3 Compensation for Growth
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 46.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.38%
EPS Next 3Y46.59%
5. Dividend
5.1 Amount
ORGO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.63
+1.74 (+44.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.08%
Inst Owner Change2.65%
Ins Owners31.49%
Ins Owner Change0.23%
Market Cap714.22M
Revenue(TTM)482.04M
Net Income(TTM)-15.59M
Analysts85
Price Target8.16 (44.94%)
Short Float %16.47%
Short Ratio16.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73%
Min EPS beat(2)-73%
Max EPS beat(2)-73%
EPS beat(4)2
Avg EPS beat(4)278.21%
Min EPS beat(4)-73%
Max EPS beat(4)688.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.3%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)-4.23%
Revenue beat(4)2
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.38%
Revenue beat(12)5
Avg Revenue beat(12)0.07%
Revenue beat(16)6
Avg Revenue beat(16)-0.09%
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-46.77%
EPS NY rev (1m)0%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 140.75 | ||
| Fwd PE | 17.81 | ||
| P/S | 1.66 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.98 | ||
| P/tB | 2.22 | ||
| EV/EBITDA | 133.2 |
EPS(TTM)0.04
EY0.71%
EPS(NY)0.32
Fwd EY5.62%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS3.39
BVpS2.85
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.38% | ||
| ROE | -4.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.58% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score3
Asset Turnover0.93
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 74.48% | ||
| Cap/Sales | 3.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.95 | ||
| Quick Ratio | 3.45 | ||
| Altman-Z | 4.09 |
F-Score3
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-63.64%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-136%
EPS Next 2Y36.38%
EPS Next 3Y46.59%
EPS Next 5YN/A
Revenue 1Y (TTM)11.29%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A
EBIT growth 1Y-221.35%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year410.89%
EBIT Next 3Y109.75%
EBIT Next 5YN/A
FCF growth 1Y-140.26%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-297.24%
OCF growth 3Y-38.8%
OCF growth 5YN/A
ORGANOGENESIS HOLDINGS INC / ORGO FAQ
Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a fundamental rating of 4 / 10 to ORGO.
What is the valuation status for ORGO stock?
ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.
How profitable is ORGANOGENESIS HOLDINGS INC (ORGO) stock?
ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 4 / 10.
What is the valuation of ORGANOGENESIS HOLDINGS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ORGANOGENESIS HOLDINGS INC (ORGO) is 140.75 and the Price/Book (PB) ratio is 1.98.
Can you provide the expected EPS growth for ORGO stock?
The Earnings per Share (EPS) of ORGANOGENESIS HOLDINGS INC (ORGO) is expected to decline by -136% in the next year.